Dr. Preetesh Jain, Assistant Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, discusses new CALQUENCE® (acalabrutinib) data presented at ASH 2020 demonstrating long-term efficacy and tolerability at three years for patients with mantle cell lymphoma (MCL).
Preetesh Jain MBBS, MD, DM, PhD is an Asst. Prof. in the Department of lymphoma and myeloma at University of Texas M.D. Anderson Cancer Ctr., Houston, TX USA. Dr. Jain has received his medical degree from India and completed at 3 year residency and 3 year medical oncology fellowship at Tata Memorial Hospital in Mumbai India. Dr. Jain moved to US in 2008, completed his PhD in molecular medicine at Feinstein Institute for medical research on IL-17 in CLL micro-environment. He then completed a 2 year clinical fellowship and leukemia Department at University of Texas M.D. Anderson Cancer Center. Then he repeated a 3 year residency in internal medicine at University of Texas Houston, then he repeated a three-year medical oncology fellowship in UT M.D. Anderson Cancer Center. He is focused on working in the field of Mantle cell lymphoma, focusing on high risk MCL, and developing newer clinical trials and translational research studies.